NovoCure Limited
NVCR
$17.96
$0.070.39%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -34.32M | -65.92M | -30.57M | -33.38M | -38.76M |
| Total Depreciation and Amortization | 3.33M | 1.74M | 2.46M | 2.86M | 2.82M |
| Total Amortization of Deferred Charges | -- | 5.14M | -- | -- | -- |
| Total Other Non-Cash Items | 22.84M | 50.99M | 23.36M | 25.42M | 31.13M |
| Change in Net Operating Assets | -27.51M | 4.61M | 15.13M | 3.38M | -26.76M |
| Cash from Operations | -35.67M | -3.45M | 10.38M | -1.72M | -31.57M |
| Capital Expenditure | -10.61M | -8.94M | -10.68M | -11.45M | -11.78M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 4.14M | -13.27M | 20.88M | -362.99M | 258.00M |
| Cash from Investing | -6.47M | -22.21M | 10.19M | -374.44M | 246.22M |
| Total Debt Issued | -- | 0.00 | -- | 96.92M | -- |
| Total Debt Repaid | -- | 0.00 | -- | -12.91M | -- |
| Issuance of Common Stock | 5.25M | 2.69M | 100.00K | 3.31M | 213.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 5.25M | 2.69M | 100.00K | 87.32M | 213.00K |
| Foreign Exchange rate Adjustments | 227.00K | -128.00K | 87.00K | -77.00K | -56.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -36.66M | -23.11M | 20.76M | -288.92M | 214.80M |